Quick Answer
Cytek Biosciences, Inc. reported Cash And Cash Equivalents At Carrying Value of $90.85 million for the year ending 2025.
- Cytek Biosciences, Inc. showed a decrease of -8.0% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Cytek Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $159.85 million | Q3 2021: $376.77 million | Q1 2022: $362.51 million | Q2 2022: $349.89 million | Q3 2022: $341.52 million | Q1 2023: $129.48 million | Q2 2023: $131.54 million | Q3 2023: $163.63 million | Q1 2024: $168.79 million | Q2 2024: $177.89 million | Q3 2024: $162.27 million | Q1 2025: $95.30 million | Q2 2025: $75.47 million | Q3 2025: $93.28 million.
- Over the full 6 years of available data (2020 to 2025), Cytek Biosciences, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 45.0%.
- Historical annual values: Fiscal year 2025: $90.85 million | Fiscal year 2024: $98.72 million | Fiscal year 2023: $167.30 million | Fiscal year 2022: $296.60 million | Fiscal year 2021: $364.62 million | Fiscal year 2020: $165.23 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: